nach oben

Die Dermatologie

Erschienen in:

06.07.2021 | Zytokine | Leitthema

Pathogenese der Hidradenitis suppurativa/Acne inversa

verfasst von: Dr. G. Nikolakis, G. Kokolakis, K. Kaleta, K. Wolk, R. Hunger, R. Sabat, C. C. Zouboulis

Erschienen in: Die Dermatologie | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Hidradenitis suppurativa (HS)/Acne inversa (AI) weist eine multifaktorielle Pathogenese auf. Neben einer sporadischen Form wird bei ca. 40 % der Patienten eine familiäre Form berichtet, für die ein autosomal-dominanter (AD) Erbgang mit einer reduzierten Genpenetranz angenommen wird. Der Phänotyp der Erkrankung mit entzündlichen Knoten, Abszessen und im Verlauf sezernierenden Fisteln lässt eine infektiöse Genese vermuten, allerdings bleibt bis heute die genaue Rolle der nachgewiesenen Bakterien bei der Pathogenese der HS unklar. Rauchen und das metabolische Syndrom werden als wichtige Triggerfaktoren der HS angesehen, wobei beim Letzteren hauptsächlich Adipositas und hormonelle Veränderungen eine pathogenetische Rolle spielen. Letztlich sind bei der überschießenden Entzündungsreaktion der HS Toll-like-Rezeptoren, antimikrobielle Peptide, Immunzellen und Schlüsselzytokine beteiligt, die auch die Ziele zukünftiger Therapien darstellen.

Boparai JK, Sharma PK (2019) Mini review on antimicrobial peptides, sources, mechanism and recent applications. Protein Pept Lett 27:4–16. https://doi.org/10.2174/0929866526666190822165812CrossRef

Canoui-Poitrine F, Le Thuaut A, Revuz JE et al (2013) Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. J Invest Dermatol 133:1506–1511. https://doi.org/10.1038/jid.2012.472CrossRefPubMed

Dréno B, Khammari A, Brocard A et al (2012) Hidradenitis suppurativa: the role of deficient cutaneous innate immunity. Arch Dermatol 148:182–186. https://doi.org/10.1001/archdermatol.2011.315CrossRefPubMed

Duchatelet S, Miskinyte S, Delage M et al (2020) Low prevalence of GSC gene mutations in a large cohort of predominantly caucasian patients with hidradenitis suppurativa. J Invest Dermatol 140:2085–2088.e14. https://doi.org/10.1016/j.jid.2019.10.025CrossRefPubMed

Emelianov VU, Bechara FG, Gläser R et al (2012) Immunohistological pointers to a possible role for excessive cathelicidin (LL-37) expression by apocrine sweat glands in the pathogenesis of hidradenitis suppurativa/acne inversa. Br J Dermatol 166:1023–1034. https://doi.org/10.1111/j.1365-2133.2011.10765.xCrossRefPubMed

Fitzsimmons J, Guilbert P, Fitzsimmons E (1985) Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 113:1–8. https://doi.org/10.1111/j.1365-2133.1985.tb02037.xCrossRefPubMed

Gao M, Wang PG, Cui Y et al (2006) Inversa acne (hidradenitis suppurativa): a case report and identification of the locus at chromosome 1p21.1–1q25.3. J Invest Dermatol 126:1302–1306. https://doi.org/10.1038/sj.jid.5700272CrossRefPubMed

Garcovich S, Tricarico PM, Nait-Meddour C et al (2020) Novel nicastrin mutation in hidradenitis suppurativa-Dowling-Degos disease clinical phenotype: more than just clinical overlap? Br J Dermatol 183:758–759. https://doi.org/10.1111/bjd.19121CrossRefPubMedPubMedCentral

Garg A, Papagermanos V, Midura M, Strunk A (2018) Incidence of hidradenitis suppurativa among tobacco smokers: a population-based retrospective analysis in the U.S.A. Br J Dermatol 178:709–714. https://doi.org/10.1111/bjd.15939CrossRefPubMed

10.

Gauntner TD (2019) Hormonal, stem cell and Notch signalling as possible mechanisms of disease in hidradenitis suppurativa: a systems-level transcriptomic analysis. Br J Dermatol 180:203–204. https://doi.org/10.1111/bjd.17093CrossRefPubMed

11.

Ghoreschi K, Balato A, Enerbäck C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397:754–766. https://doi.org/10.1016/S0140-6736(21)00184-7CrossRefPubMed

12.

Giamarellos-Bourboulis EJ, Platzer M, Karagiannidis I et al (2016) High copy numbers of β‑Defensin cluster on 8p23.1, confer genetic susceptibility, and modulate the physical course of hidradenitis suppurativa/acne Inversa. J Invest Dermatol 136:1592–1598. https://doi.org/10.1016/j.jid.2016.04.021CrossRefPubMed

13.

Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 82:1045–1058. https://doi.org/10.1016/j.jaad.2019.08.090CrossRefPubMed

14.

Guet-Revillet H, Coignard-Biehler H, Jais JP et al (2014) Bacterial pathogens associated with hidradenitis suppurativa, France. Emerg Infect Dis 20:1990–1998. https://doi.org/10.3201/eid2012.140064CrossRefPubMedPubMedCentral

15.

Guet-Revillet H, Jais JP, Ungeheuer MN et al (2017) The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study. Clin Infect Dis 65:282–291. https://doi.org/10.1093/cid/cix285CrossRefPubMed

16.

Gulliver W, Zouboulis CC, Prens E et al (2016) Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord 17:343–351. https://doi.org/10.1007/s11154-016-9328-5CrossRefPubMedPubMedCentral

17.

Hessam S, Gambichler T, Skrygan M et al (2021) Increased expression profile of NCSTN, notch and PI3K/AKT3 in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 35:203–210. https://doi.org/10.1111/jdv.16962CrossRefPubMed

18.

Hotz C, Boniotto M, Guguin A et al (2016) Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa. J Invest Dermatol 136:1768–1780. https://doi.org/10.1016/j.jid.2016.04.036CrossRefPubMed

19.

Hunger RE, Surovy AM, Hassan AS et al (2008) Toll-like receptor 2 is highly expressed in lesions of acne inversa and colocalizes with C‑type lectin receptor. Br J Dermatol 158:691–697. https://doi.org/10.1111/j.1365-2133.2007.08425.xCrossRefPubMed

20.

Ingram JR (2016) The genetics of hidradenitis suppurativa. Dermatol Clin 34:23–28. https://doi.org/10.1016/j.det.2015.07.002CrossRefPubMed

21.

Ingram JR, Wood M, John B et al (2013) Absence of pathogenic γ‑secretase mutations in a South Wales cohort of familial and sporadic hidradenitis suppurativa (acne inversa). Br J Dermatol 168:874–876. https://doi.org/10.1111/bjd.12048CrossRefPubMed

22.

Jenei A, Dajnoki Z, Medgyesi B et al (2019) Apocrine gland-rich skin has a non-inflammatory IL-17-related immune milieu, that turns to inflammatory IL-17-mediated disease in hidradenitis Suppurativa. J Invest Dermatol 139:964–968. https://doi.org/10.1016/j.jid.2018.10.020CrossRefPubMed

23.

Jfri AH, O’Brien EA, Litvinov IV et al (2019) Hidradenitis suppurativa: comprehensive review of predisposing genetic mutations and changes. J Cutan Med Surg 23:519–527. https://doi.org/10.1177/1203475419852049CrossRefPubMed

24.

Kaleta KP, Nikolakis G, Hossini A et al (2021) Metabolic disorders/obesity is a primary risk factor in hidradenitis suppurativa—an immunohistochemical real-world approach. Dermatology. https://doi.org/10.1159/000517017CrossRefPubMed

25.

Karagiannidis I, Nikolakis G, Sabat R, Zouboulis CC (2016) Hidradenitis suppurativa/Acne inversa: an endocrine skin disorder? Rev Endocr Metab Disord 17:335–341. https://doi.org/10.1007/s11154-016-9366-zCrossRefPubMed

26.

Karagiannidis I, Nikolakis G, Zouboulis CC (2016) Endocrinologic aspects of hidradenitis suppurativa. Dermatol Clin 34:45–49. https://doi.org/10.1016/j.det.2015.08.005CrossRefPubMed

27.

Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 11:373–384. https://doi.org/10.1038/ni.1863CrossRefPubMed

28.

Kimball AB, Okun MM, Williams DA et al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med 375:422–434. https://doi.org/10.1056/NEJMoa1504370CrossRefPubMed

29.

Kokolakis G, Wolk K, Schneider-Burrus S et al (2020) Delayed diagnosis of hidradenitis suppurativa and its effect on patients and healthcare system. Dermatology 236:421–430. https://doi.org/10.1159/000508787CrossRefPubMed

30.

Kurzen H, Kurokawa I, Jemec GBE et al (2008) What causes hidradenitis suppurativa? Exp Dermatol 17:455–456. https://doi.org/10.1111/j.1600-0625.2008.00712_1.xCrossRefPubMed

31.

Li X, Jiang L, Huang Y et al (2020) A gene dysfunction module reveals the underlying pathogenesis of hidradenitis suppurativa: an update. Australas J Dermatol 61:e10–e14. https://doi.org/10.1111/ajd.13107CrossRefPubMed

32.

Naik HB, Jo JH, Paul M, Kong HH (2020) Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa. J Invest Dermatol 140:922–925.e3. https://doi.org/10.1016/j.jid.2019.08.445CrossRefPubMed

33.

Nikolakis G, Join-Lambert O, Karagiannidis I et al (2015) Bacteriology of hidradenitis suppurativa/acne inversa: a review. J Am Acad Dermatol 73:S12–S18. https://doi.org/10.1016/j.jaad.2015.07.041CrossRefPubMed

34.

Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2020) Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. Dermatology. https://doi.org/10.1159/000509873CrossRefPubMed

35.

Nikolakis G, Karagiannidis I, Vaiopoulos AG et al (2020) Endocrinological mechanisms in the pathophysiology of hidradenitis suppurativa. Hautarzt 71:762–771. https://doi.org/10.1007/s00105-020-04679-zCrossRefPubMed

36.

Nikolakis G, Kyrgidis A, Zouboulis CC (2019) Is there a role for antiandrogen therapy for hidradenitis suppurativa? A systematic review of published data. Am J Clin Dermatol 20:503–513. https://doi.org/10.1007/s40257-019-00442-wCrossRefPubMed

37.

Parsek MR, Singh PK (2003) Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 57:677–701. https://doi.org/10.1146/annurev.micro.57.030502.090720CrossRefPubMed

38.

Ring HC, Bay L, Nilsson M et al (2017) Bacterial biofilm in chronic lesions of hidradenitis suppurativa. Br J Dermatol 176:993–1000. https://doi.org/10.1111/bjd.15007CrossRefPubMed

39.

Ring HC, Sigsgaard V, Thorsen J et al (2019) The microbiome of tunnels in hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol 33:1775–1780. https://doi.org/10.1111/jdv.15597CrossRefPubMed

40.

Ring HC, Thorsen J, Saunte DM et al (2017) The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls. JAMA Dermatol 153:897–905. https://doi.org/10.1001/jamadermatol.2017.0904CrossRefPubMedPubMedCentral

41.

Ring HC, Thorsen J, Saunte DM et al (2018) Moderate to severe hidradenitis suppurativa patients do not have an altered bacterial composition in peripheral blood compared to healthy controls. J Eur Acad Dermatol Venereol 32:125–128. https://doi.org/10.1111/jdv.14538CrossRefPubMed

42.

Sabat R, Chanwangpong A, Schneider-Burrus S et al (2012) Increased prevalence of metabolic syndrome in patients with Acne inversa. Plos One 7:e31810. https://doi.org/10.1371/journal.pone.0031810CrossRefPubMedPubMedCentral

43.

Sabat R, Jemec GBE, Matusiak Ł et al (2020) Hidradenitis suppurativa. Nat Rev Dis Primers. https://doi.org/10.1038/s41572-020-0149-1CrossRefPubMed

44.

Sabat R, Wolk K, Loyal L et al (2019) T cell pathology in skin inflammation. Semin Immunopathol 41:359–377. https://doi.org/10.1007/s00281-019-00742-7CrossRefPubMedPubMedCentral

45.

Savva A, Kanni T, Damoraki G et al (2013) Impact of Toll-like receptor‑4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa. Br J Dermatol 168:311–317. https://doi.org/10.1111/bjd.12105CrossRefPubMed

46.

Schlapbach C, Hänni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790–798. https://doi.org/10.1016/j.jaad.2010.07.010CrossRefPubMed

47.

Schneider-Burrus S, Lux G, van der Linde K et al (2021) Hidradenitis suppurativa-prevalence analyses of German statutory health insurance data. J Eur Acad Dermatol Venereol 35:e32–e35. https://doi.org/10.1111/jdv.16783CrossRefPubMed

48.

Schneider-Burrus S, Tsaousi A, Barbus S et al (2021) Features associated with quality of life impairment in hidradenitis suppurativa patients. Front Med 8:538. https://doi.org/10.3389/FMED.2021.676241CrossRef

49.

Schneider-Burrus S, Witte-Haendel E, Christou D et al (2017) High prevalence of back pain and axial spondyloarthropathy in patients with hidradenitis suppurativa. Dermatology 232:606–612. https://doi.org/10.1159/000448838CrossRef

50.

Shalom G, Freud T, Harman-Boehm I et al (2015) Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol 173:464–470. https://doi.org/10.1111/bjd.13777CrossRefPubMed

51.

Van Straalen KR, Prens EP, Willemsen G et al (2020) Contribution of genetics to the susceptibility to hidradenitis suppurativa in a large, cross-sectional Dutch twin cohort. JAMA Dermatol 156:1359–1362. https://doi.org/10.1001/jamadermatol.2020.3630CrossRefPubMed

52.

Tricarico PM, Boniotto M, Genovese G et al (2019) An integrated approach to unravel hidradenitis suppurativa etiopathogenesis. Front Immunol 10:1–13. https://doi.org/10.3389/fimmu.2019.00892CrossRef

53.

Volk HD, Asadullah K, Gallagher G et al (2001) IL-10 and its homologs: Important immune mediators and emerging immunotherapeutic agents. Trends Immunol 22:414–7. https://doi.org/10.1016/S1471-4906(01)01985-8CrossRefPubMed

54.

Vossen ARJV, van Straalen KR, Swagemakers SMA et al (2020) A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significance. J Eur Acad Dermatol Venereol 34:2353–2361. https://doi.org/10.1111/jdv.16310CrossRefPubMedPubMedCentral

55.

Wang Z, Yan Y, Wang B (2020) γ‑secretase genetics of hidradenitis suppurativa: a systematic literature review. Dermatology. https://doi.org/10.1159/000512455CrossRefPubMed

56.

Von der Werth JM, Williams HC, Raeburn JA (2000) The clinical genetics of hidradenitis suppurativa revisited. Br J Dermatol 142:947–953. https://doi.org/10.1046/j.1365-2133.2000.03476.xCrossRef

57.

Williams SC, Frew JW, Krueger JG (2020) A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. Exp Dermatol. https://doi.org/10.1111/exd.14141CrossRefPubMedPubMedCentral

58.

Witte-Händel E, Wolk K, Tsaousi A et al (2019) The IL‑1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol 139:1294–1305. https://doi.org/10.1016/j.jid.2018.11.018CrossRefPubMed

59.

Wittebole X, Hahm S, Coyle SM et al (2007) Nicotine exposure alters in vivo human responses to endotoxin. Clin Exp Immunol 147:28–34. https://doi.org/10.1111/j.1365-2249.2006.03248.xCrossRefPubMedPubMedCentral

60.

Wolk K, Brembach TC, Šimaitė D et al (2021) Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa. Br J Dermatol. https://doi.org/10.1111/bjd.19795CrossRefPubMed

61.

Wolk K, Join-Lambert O, Sabat R (2020) Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol 183:999–1010. https://doi.org/10.1111/bjd.19556CrossRefPubMed

62.

Wolk K, Kunz S, Witte E et al (2004) IL-22 increases the innate immunity of tissues. Immunity 21:241–254. https://doi.org/10.1016/j.immuni.2004.07.007CrossRefPubMed

63.

Wolk K, Sabat R (2016) Adipokines in psoriasis: an important link between skin inflammation and metabolic alterations. Rev Endocr Metab Disord 17:305–317. https://doi.org/10.1007/s11154-016-9381-0CrossRefPubMed

64.

Wolk K, Warszawska K, Hoeflich C et al (2011) Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne Inversa. J Immunol 186:1228–1239. https://doi.org/10.4049/jimmunol.0903907CrossRefPubMed

65.

Wolk K, Wenzel J, Tsaousi A et al (2017) Lipocalin‑2 is expressed by activated granulocytes and keratinocytes in affected skin and reflects disease activity in acne inversa/hidradenitis suppurativa. Br J Dermatol 177:1385–1393. https://doi.org/10.1111/bjd.15424CrossRefPubMed

66.

Xu H, Xiao X, Hui Y et al (2016) Phenotype of 53 Chinese individuals with nicastrin gene mutations in association with familial hidradenitis suppurativa (acne inversa). Br J Dermatol 174:927–929. https://doi.org/10.1111/bjd.14268CrossRefPubMed

67.

Zouboulis CC, Benhadou F, Byrd AS et al (2020) What causes hidradenitis suppurativa ?—15 years after. Exp Dermatol. https://doi.org/10.1111/exd.14214CrossRefPubMed

68.

Zouboulis CC, Desai N, Emtestam L et al (2015) European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 29:619–644. https://doi.org/10.1111/jdv.12966CrossRefPubMed

69.

Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ et al (2021) Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 30:8–17. https://doi.org/10.1111/exd.14338CrossRefPubMed

70.

Zouboulis CC, Del Marmol V, Mrowietz U et al (2015) Hidradenitis suppurativa/acne inversa: criteria for diagnosis, severity assessment, classification and disease evaluation. Dermatology 231:184–190. https://doi.org/10.1159/000431175CrossRefPubMed

71.

Zouboulis CC, Nogueira da Costa A, Fimmel S, Zouboulis KC (2020) Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. J Eur Acad Dermatol Venereol. https://doi.org/10.1111/jdv.16264CrossRefPubMedPubMedCentral

72.

Zouboulis CC, Nogueira da Costa A, Makrantonaki E et al (2020) Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 34:846–861. https://doi.org/10.1111/jdv.16147CrossRefPubMed

73.

Higgins R, Pink A, Hunger R et al (2017) Generalized comedones, acne, and Hidradenitis Suppurativa in a patient with an FGFR2 missense mutation. Front Med 4:16. https://doi.org/10.3389/fmed.2017.00016CrossRef

74.

Marzuillo P, Piccolo V, Mascolo M et al (2018) Patients affected by dent disease 2 could be predisposed to hidradenitis suppurativa. J Eur Acad Dermatol Venereol 32:e309–e311. https://doi.org/10.1111/jdv.14860CrossRefPubMed

75.

Kim JE, Cho BK, Cho DH, et al (2013) Expression of Hypothalamic-pituitary-adrenal axis in common skin diseases:Evidence of its association with stress-related Disease Activity. Acta Derm Venereol 93:387–93. https://doi.org/10.2340/00015555-1557CrossRefPubMed

Titel: Pathogenese der Hidradenitis suppurativa/Acne inversa
verfasst von: Dr. G. Nikolakis
G. Kokolakis
K. Kaleta
K. Wolk
R. Hunger
R. Sabat
C. C. Zouboulis
Publikationsdatum: 06.07.2021
Verlag: Springer Medizin
Schlagwörter: Zytokine
Acne inversa
Erschienen in: Die Dermatologie / Ausgabe 8/2021
Print ISSN: 2731-7005
Elektronische ISSN: 2731-7013
DOI: https://doi.org/10.1007/s00105-021-04853-x

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

22.04.2024 | DGIM 2024 | Nachrichten

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Pathogenese der Hidradenitis suppurativa/Acne inversa

Zusammenfassung

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2021

Klinische, pathologische und molekulare Biomarker der Hidradenitis suppurativa/Acne inversa

Lokale und neue apparative Therapien der milden Hidradenitis suppurativa

Hidradenitis suppurativa/Acne inversa: Von „orphan disease“ zu heilbarer entzündlicher Hauterkrankung

Operative Optionen bei Hidradenitis suppurativa – ein Update

Bedarf von Real-World-klinischen Therapiestudien für die Hidradenitis suppurativa/Acne inversa

Blutung oder Melanom?

Leitlinien kompakt für die Dermatologie

Neu im Fachgebiet Dermatologie

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Update Dermatologie